Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
James A DavisKatelynn GrangerAlex SakowskiSara GoodwinAmanda HerbstDeidra SmithLindsey HendricksonVictoria R NacharPublished in: Expert review of hematology (2023)